Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli
- PMID: 2836522
- DOI: 10.1093/infdis/157.6.1203
Antigenic and immunogenic properties of a hepatitis A virus capsid protein expressed in Escherichia coli
Abstract
We have constructed a recombinant plasmid producing, in bacteria, a hepatitis A virus (HAV) capsid protein that may be useful as a subunit vaccine. HAV VP1 coding sequences were fused in-frame to NH2-terminal Escherichia coli TrpE coding sequences under the control of the tryptophan promoter. In the absence of exogenous tryptophan, E. coli containing this recombinant plasmid produced high levels of an 88-kilodalton fusion protein that was recognized in immunoblots by antibodies to TrpE and HAV. The TrpE/HAV VP1 protein was gel-purified and used to immunize rabbits. The resulting antiserum reacted with denatured HAV VP1 in immunoblots but did not react with intact virus. However, subsequent inoculation of an immunized animal with a subimmunogenic dose of inactivated, whole HAV resulted in the rapid appearance of a stable, virus-neutralizing antibody response.
Similar articles
-
Immunologic priming with recombinant hepatitis A virus capsid proteins produced in Escherichia coli.J Virol. 1991 May;65(5):2686-90. doi: 10.1128/JVI.65.5.2686-2690.1991. J Virol. 1991. PMID: 1850041 Free PMC article.
-
Recombinant proteins VP1 and VP3 of hepatitis A virus prime for neutralizing response.J Med Virol. 1990 Aug;31(4):277-83. doi: 10.1002/jmv.1890310407. J Med Virol. 1990. PMID: 2176673
-
Immunogenicity and antigenicity of chimeric picornaviruses which express hepatitis A virus (HAV) peptide sequences: evidence for a neutralization domain near the amino terminus of VP1 of HAV.Virology. 1992 May;188(1):285-95. doi: 10.1016/0042-6822(92)90758-h. Virology. 1992. PMID: 1314456
-
Possible approaches to develop vaccines against hepatitis A.Vaccine. 1992;10 Suppl 1:S48-52. doi: 10.1016/0264-410x(92)90542-r. Vaccine. 1992. PMID: 1335659 Review.
-
Genetic, antigenic and biological differences between strains of hepatitis A virus.Vaccine. 1992;10 Suppl 1:S40-4. doi: 10.1016/0264-410x(92)90540-z. Vaccine. 1992. PMID: 1335657 Review.
Cited by
-
Prophylactic treatment regimens for the prevention of hepatitis A. Current concepts.Drugs. 1991 Jun;41(6):883-8. doi: 10.2165/00003495-199141060-00006. Drugs. 1991. PMID: 1715265 Review.
-
Immunologic priming with recombinant hepatitis A virus capsid proteins produced in Escherichia coli.J Virol. 1991 May;65(5):2686-90. doi: 10.1128/JVI.65.5.2686-2690.1991. J Virol. 1991. PMID: 1850041 Free PMC article.
-
Solubility as a limiting factor for expression of hepatitis A virus proteins in insect cell-baculovirus system.Mem Inst Oswaldo Cruz. 2016 Aug;111(8):535-8. doi: 10.1590/0074-02760160153. Epub 2016 Jul 11. Mem Inst Oswaldo Cruz. 2016. PMID: 27581123 Free PMC article.
-
Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays.J Clin Microbiol. 1998 Jul;36(7):2014-8. doi: 10.1128/JCM.36.7.2014-2018.1998. J Clin Microbiol. 1998. PMID: 9650953 Free PMC article.
-
Identification of an immunodominant antigenic site involving the capsid protein VP3 of hepatitis A virus.Proc Natl Acad Sci U S A. 1988 Nov;85(21):8281-5. doi: 10.1073/pnas.85.21.8281. Proc Natl Acad Sci U S A. 1988. PMID: 2460866 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources